전이성 포도막 악성 흑색종(MUM) : 시장 인사이트, 역학 및 시장 예측(-2034년)

Metastatic Uveal Melanoma (MUM) - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,093,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,640,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,186,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 33,280,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

앞으로 몇 년동안 전이성 포도막 악성 흑색종(MUM) 시장은 이 질환에 대한 인식이 높아지고 전 세계 의료비 지출이 증가함에 따라 변화할 것으로 예상됩니다.

기업과 연구기관들은 전이성 포도막 악성 흑색종(MUM) 연구개발에 영향을 미칠 수 있는 과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다. 주요 기업들이 전이성 포도막 악성 흑색종(MUM) 치료제 개발에 참여하고 있습니다. 새로운 치료법의 등장은 전이성 포도막 악성 흑색종(MUM) 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 전이성 포도막 악성 흑색종(MUM) 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등을 제공합니다.

목차

제1장 주요 인사이트

제2장 전이성 포도막 악성 흑색종(MUM) 주요 요약

제3장 전이성 포도막 악성 흑색종(MUM) 경쟁 정보 분석

제4장 전이성 포도막 악성 흑색종(MUM) : 시장 개요

제5장 전이성 포도막 악성 흑색종(MUM) : 질환 배경과 개요

• 서론
• 징후와 증상
• 병태생리학
• 위험 요인
• 진단

제6장 환자 동향

제7장 전이성 포도막 악성 흑색종(MUM) 역학과 환자 인구

• 역학 주요 조사 결과
• 전제와 근거 : 주요 7개국
• 역학 시나리오 : 주요 7개국
• 미국
• 유럽 5개국
• 일본

제8장 치료 알고리즘, 현재의 치료 및 의료 행위

제9장 미충족 요구

제10장 전이성 포도막 악성 흑색종(MUM) 치료의 주요 평가 항목

제11장 출시 제품

제12장 새로운 치료법

제13장 전이성 포도막 악성 흑색종(MUM) : 주요 7개국 시장 분석

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

• 미국 : 시장 규모
• 유럽 5개국 : 시장 규모와 전망
• 독일 시장 규모
• 프랑스 시장 규모
• 이탈리아 시장 규모
• 스페인 시장 규모
• 영국 시장 규모
• 일본 시장 규모

제16장 전이성 포도막 악성 흑색종(MUM) 접근 및 상환 개요

제17장 KOL(Key Opinion Leader)의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight에 대해

LSH

영문 목차

영문목차

DelveInsight's "Metastatic Uveal Melanoma (MUM) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Metastatic Uveal Melanoma (MUM), historical and forecasted epidemiology as well as the Metastatic Uveal Melanoma (MUM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Metastatic Uveal Melanoma (MUM) market report provides current treatment practices, emerging drugs, Metastatic Uveal Melanoma (MUM) market share of the individual therapies, current and forecasted Metastatic Uveal Melanoma (MUM) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Metastatic Uveal Melanoma (MUM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Metastatic Uveal Melanoma (MUM) Disease Understanding and Treatment Algorithm

The DelveInsight Metastatic Uveal Melanoma (MUM) market report gives a thorough understanding of the Metastatic Uveal Melanoma (MUM) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Metastatic Uveal Melanoma (MUM).

Treatment

It covers the details of conventional and current medical therapies available in the Metastatic Uveal Melanoma (MUM) market for the treatment of the condition. It also provides Metastatic Uveal Melanoma (MUM) treatment algorithms and guidelines in the United States, Europe, and Japan.

Metastatic Uveal Melanoma (MUM) Epidemiology

The Metastatic Uveal Melanoma (MUM) epidemiology division provide insights about historical and current Metastatic Uveal Melanoma (MUM) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Uveal Melanoma (MUM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Metastatic Uveal Melanoma (MUM) Epidemiology

The epidemiology segment also provides the Metastatic Uveal Melanoma (MUM) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic Uveal Melanoma (MUM) Drug Chapters

Drug chapter segment of the Metastatic Uveal Melanoma (MUM) report encloses the detailed analysis of Metastatic Uveal Melanoma (MUM) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Metastatic Uveal Melanoma (MUM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Metastatic Uveal Melanoma (MUM) treatment.

Metastatic Uveal Melanoma (MUM) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Metastatic Uveal Melanoma (MUM) treatment.

Metastatic Uveal Melanoma (MUM) Market Outlook

The Metastatic Uveal Melanoma (MUM) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Metastatic Uveal Melanoma (MUM) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Metastatic Uveal Melanoma (MUM) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Metastatic Uveal Melanoma (MUM) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Metastatic Uveal Melanoma (MUM) market in 7MM.

The United States Market Outlook

This section provides the total Metastatic Uveal Melanoma (MUM) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Metastatic Uveal Melanoma (MUM) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Metastatic Uveal Melanoma (MUM) market size and market size by therapies in Japan is also mentioned.

Metastatic Uveal Melanoma (MUM) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Metastatic Uveal Melanoma (MUM) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Metastatic Uveal Melanoma (MUM) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Metastatic Uveal Melanoma (MUM) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Metastatic Uveal Melanoma (MUM) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Metastatic Uveal Melanoma (MUM) emerging therapies.

Reimbursement Scenario in Metastatic Uveal Melanoma (MUM)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Metastatic Uveal Melanoma (MUM) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Metastatic Uveal Melanoma (MUM) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Metastatic Uveal Melanoma (MUM) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Metastatic Uveal Melanoma (MUM), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Metastatic Uveal Melanoma (MUM) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Metastatic Uveal Melanoma (MUM) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Metastatic Uveal Melanoma (MUM) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Metastatic Uveal Melanoma (MUM) market

Report Highlights:

• In the coming years, Metastatic Uveal Melanoma (MUM) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Uveal Melanoma (MUM) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Metastatic Uveal Melanoma (MUM). Launch of emerging therapies will significantly impact the Metastatic Uveal Melanoma (MUM) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metastatic Uveal Melanoma (MUM)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Metastatic Uveal Melanoma (MUM) Report Insights

• Patient Population
• Therapeutic Approaches
• Metastatic Uveal Melanoma (MUM) Pipeline Analysis
• Metastatic Uveal Melanoma (MUM) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Metastatic Uveal Melanoma (MUM) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Metastatic Uveal Melanoma (MUM) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Metastatic Uveal Melanoma (MUM) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Metastatic Uveal Melanoma (MUM) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Metastatic Uveal Melanoma (MUM) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Metastatic Uveal Melanoma (MUM) market size during the forecast period (2024-2034)?
• At what CAGR, the Metastatic Uveal Melanoma (MUM) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Metastatic Uveal Melanoma (MUM) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Metastatic Uveal Melanoma (MUM) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Metastatic Uveal Melanoma (MUM)?
• What is the historical Metastatic Uveal Melanoma (MUM) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Metastatic Uveal Melanoma (MUM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Metastatic Uveal Melanoma (MUM)?
• Out of all 7MM countries, which country would have the highest prevalent population of Metastatic Uveal Melanoma (MUM) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Metastatic Uveal Melanoma (MUM) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Metastatic Uveal Melanoma (MUM) in the USA, Europe, and Japan?
• What are the Metastatic Uveal Melanoma (MUM) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Metastatic Uveal Melanoma (MUM)?
• How many therapies are developed by each company for Metastatic Uveal Melanoma (MUM) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Metastatic Uveal Melanoma (MUM) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Metastatic Uveal Melanoma (MUM) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Uveal Melanoma (MUM) and their status?
• What are the key designations that have been granted for the emerging therapies for Metastatic Uveal Melanoma (MUM)?
• What are the global historical and forecasted market of Metastatic Uveal Melanoma (MUM)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Uveal Melanoma (MUM) market
• To understand the future market competition in the Metastatic Uveal Melanoma (MUM) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Uveal Melanoma (MUM) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Uveal Melanoma (MUM) market
• To understand the future market competition in the Metastatic Uveal Melanoma (MUM) market

Table of Contents

1. Key Insights

2. Executive Summary of Metastatic Uveal Melanoma (MUM)

3. Competitive Intelligence Analysis for Metastatic Uveal Melanoma (MUM)

4. Metastatic Uveal Melanoma (MUM): Market Overview at a Glance

• 4.1. Metastatic Uveal Melanoma (MUM) Total Market Share (%) Distribution in 2020
• 4.2. Metastatic Uveal Melanoma (MUM) Total Market Share (%) Distribution in 2034

5. Metastatic Uveal Melanoma (MUM): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Metastatic Uveal Melanoma (MUM) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Metastatic Uveal Melanoma (MUM) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Metastatic Uveal Melanoma (MUM) Treatment and Management
• 8.2. Metastatic Uveal Melanoma (MUM) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Metastatic Uveal Melanoma (MUM) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Metastatic Uveal Melanoma (MUM): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Metastatic Uveal Melanoma (MUM) Market Size in 7MM
• 13.3. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Metastatic Uveal Melanoma (MUM) Total Market Size in the United States
  • 15.1.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Metastatic Uveal Melanoma (MUM) Total Market Size in Germany
  • 15.3.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Metastatic Uveal Melanoma (MUM) Total Market Size in France
  • 15.4.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Metastatic Uveal Melanoma (MUM) Total Market Size in Italy
  • 15.5.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Metastatic Uveal Melanoma (MUM) Total Market Size in Spain
  • 15.6.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Metastatic Uveal Melanoma (MUM) Total Market Size in the United Kingdom
  • 15.7.2. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Metastatic Uveal Melanoma (MUM) Total Market Size in Japan
  • 15.8.3. Metastatic Uveal Melanoma (MUM) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Metastatic Uveal Melanoma (MUM)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료